Parikh SM.
Curr Opin Hematol. 2017Sep;24(5):432-438. doi: 10.1097/MOH.0000000000000361. Review.
PMID: 28582314
Parikh SM.
Curr Opin Hematol. 2017Sep;24(5):432-438. doi: 10.1097/MOH.0000000000000361. Review.
PMID: 28582314
About
Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.